Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug 24;97(8):378-388.
doi: 10.1212/WNL.0000000000012323. Epub 2021 Jun 4.

Secondary Progressive Multiple Sclerosis: New Insights

Affiliations
Review

Secondary Progressive Multiple Sclerosis: New Insights

Bruce A C Cree et al. Neurology. .

Abstract

In most cases, multiple sclerosis (MS) begins with a relapsing-remitting course followed by insidious disability worsening that is independent from clinically apparent relapses and is termed secondary progressive MS (SMPS). Major differences exist between relapsing-remitting MS (RRMS) and SPMS, especially regarding therapeutic response to treatment. This review provides an overview of the pathology, differentiation, and challenges in the diagnosis and treatment of SPMS. We emphasize the criticality of conversion from a relapsing-remitting to a secondary progressive disease course not only because such conversion is evidence of disability progression, but also because, until recently, treatments that effectively reduced disability progression in relapsing MS were not proven to be effective in SPMS. Clear clinical, imaging, immunologic, or pathologic criteria marking the transition from RRMS to SPMS have not yet been established. Early identification of SPMS will require tools that, together with the use of appropriate treatments, may result in better long-term outcomes for the population of patients with SPMS.

PubMed Disclaimer

Figures

Figure
Figure. Delay in Secondary Progressive Multiple Sclerosis (SPMS) Diagnosis
Reprinted from Katz Sand I, Krieger S, Farrell C, Miller AE. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis. Mult Scler 2014;20:1654–165740 (copyright 2014 by SAGE Publications). Reprinted with permission of SAGE Publications, Ltd. EDSS = Expanded Disability Status Scale; MS = multiple sclerosis; RRMS = relapsing-remitting multiple sclerosis; SPMS = secondary progressive multiple sclerosis.

References

    1. Lassmann H. Pathogenic mechanisms associated with different clinical courses of multiple sclerosis. Front Immunol. 2018;9:3116. - PMC - PubMed
    1. Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol. 2012;8(11):647-656. - PubMed
    1. Kappos L, Bar-Or A, Cree BAC, et al. . Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263-1273. - PubMed
    1. Novartis Pharmaceuticals Corporation. Siponimod highlights of prescribing information. Accessed January 16, 2020, novartis.us/sites/www.novartis.us/files/mayzent.pdf.
    1. Novartis Pharma GmbH. Mayzent summary of product characteristics. Accessed February 5, 2020. ema.europa.eu/en/documents/product-information/mayzent-epar-product-info....

Publication types

MeSH terms